The company

The pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications.

Company

Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader – a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important risk predictor of diabetes and its complications.

Mission

DiagnOptics is committed to the technological development and innovation in AGEs’ detection through continuous dedication on non-invasive biomedical technologies.

Our mission is to improve the standard of clinical diagnosis and risk assessment on diabetes and its complications.

History

1995 – Dr. Smit and his co-workers made a coincidental finding of increased autofluorescence of the skin in many diabetes patients when they were performing fluorescein capillary leakage studies in diabetes.

1996 – Dr. Smit and Dr. Graaff developed dedicated prototypes to assess skin autofluorescence in humans.

1998 – The first clinical studies in diabetes and renal failure were started with an advanced prototype of the AGE Reader in the University Hospital Groningen, The Netherlands.

1999 – Filed patent application for the AGE Reader and published the first scientific report on the clinical use of the AGE Reader prototype in diabetic patients

2000 – Initiated the first large scale follow-up study in the Zwolle region

2003 – Dr. Smit and Dr. Graaf founded DiagnOptics in Groningen, the Netherlands

2004 – The first clinical study on the AGE Reader was published in Diabetologia

2005 – The AGE Reader was first shown to future users (EASD, Athens 2005)

2006 – AGE Reader received CE approval for commercialisation in Europe

2009 – AGE Reader CU (Compact Unit) received CE approval

2010 – Diagnoptics received ISO 13485 certification for its Quality Management System

2011 – Diab-spot was first shown to future users (Prediabetes, Madrid 2011)

2011 – Diab-spot received CE approval

2012 – First demonstration of the AGE Reader mu at the EASD 2012 in Berlin

2013 – AGE Reader mu received CE approval

2014 – Installed base > 2000 units

2015 – Ranked 33rd in Deloitte Technology Fast50 and sector winner Life Sciences

 

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

Contact

Our contact details

Diagnoptics Technologies B.V.
Aarhusweg 4-9
9723 JJ Groningen
The Netherlands

Tel: +31 (0)50 589 0612
Fax: +31 (0)50 589 0613
E-mail: info@diagnoptics.com


Follow us on LinkedIn

About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.